Overview

Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

Status:
Recruiting

Trial end date:
2027-06-14

Target enrollment:
0

Participant gender:
All

Summary

The study will determine the optimal dosing regimen of LNA043 in patients with knee osteoarthritis (OA).

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Novartis Pharmaceuticals

Criteria

Inclusion Criteria:

- Males and females between 40 and 75 years of age

- Body mass index (BMI) < 40 kg/m2

- Diagnosis of primary tibiofemoral knee OA by standard American College of Rheumatology
clinical and radiographic criteria

- and other criteria as specified by the protocol

Exclusion Criteria:

- Participants with radiographic knee OA K-L grade = 4 on the non-target knee

- Arthroscopy of the target knee within the 6 months prior to Screening

- Hemoglobin < 8.5 g/dL (85 g/L) or platelet count < 100,000/μL

- and other criteria as specified by the protocol